The White House announced nine additional voluntary most-favored-nation (MFN) drug pricing deals with mid-sized and large pharma companies, expanding coverage beyond the initial group previously highlighted by the administration. The latest signatories include Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB. The agreements aim to align U.S. prescription drug pricing with the lowest prices paid by peer nations and extend reduced pricing access to Medicaid programs. The White House-linked reporting also points to domestic manufacturing investment commitments and related procurement of active pharmaceutical ingredients for the Strategic Active Pharmaceutical Ingredients Reserve. Separate analysis around the broader MFN push continues to raise questions about which companies are included, how tariffs may be avoided, and whether voluntary commitments deliver meaningful improvements in patient access at the point of sale.